Media headlines about Fluidigm (NASDAQ:FLDM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fluidigm earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.1853139472863 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Fluidigm (NASDAQ:FLDM) traded down $0.05 during midday trading on Wednesday, hitting $6.80. 79,890 shares of the company’s stock were exchanged, compared to its average volume of 218,845. The company has a market capitalization of $264.31, a PE ratio of -3.61 and a beta of 2.97. The company has a current ratio of 2.83, a quick ratio of 2.38 and a debt-to-equity ratio of 6.31. Fluidigm has a 12-month low of $2.52 and a 12-month high of $8.38.
Fluidigm (NASDAQ:FLDM) last released its earnings results on Thursday, February 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Fluidigm had a negative net margin of 59.38% and a negative return on equity of 118.56%. The firm had revenue of $27.75 million during the quarter, compared to analyst estimates of $27.14 million. During the same quarter in the previous year, the firm earned ($0.32) EPS. Fluidigm’s quarterly revenue was up 10.6% on a year-over-year basis. analysts expect that Fluidigm will post -0.93 EPS for the current year.
In other news, insider Levin Capital Strategies, L.P. acquired 27,100 shares of Fluidigm stock in a transaction on Wednesday, December 27th. The stock was acquired at an average cost of $5.88 per share, with a total value of $159,348.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders acquired 750,191 shares of company stock valued at $4,656,189. Insiders own 4.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/14/fluidigm-fldm-given-daily-media-impact-score-of-0-22/1923797.html.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.